RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
RAS mutations are the most common oncogenic drivers across human cancers, but there remains a paucity of clinically-validated pharmacological inhibitors of RAS, as druggable pockets have proven difficult to identify. Here, we identify two RAS-binding Affimer proteins, K3 and K6, that inhibit nucleotide exchange and downstream signaling pathways with distinct isoform and mutant profiles. Affimer K6 binds in the SI/SII pocket, whilst Affimer K3 is a non-covalent inhibitor of the SII region that reveals a conformer of wild-type RAS with a large, druggable SII/α3 pocket. Competitive NanoBRET between the RAS-binding Affimers and known RAS binding small-molecules demonstrates the potential to use Affimers as tools to identify pharmacophores. This work highlights the potential of using biologics with small interface surfaces to select unseen, druggable conformations in conjunction with pharmacophore identification for hard-to-drug proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A subcellular map of the human proteome
Thul, P. J., Åkesson, L., Wiking, M., Mahdessian, D., Geladaki, A., Ait Blal, H., Alm, T., Asplund, A., Björk, L., Breckels, L. M., et al. (2017) · Science · doi:10.1126/science.aal3321 · Cited by 2,813
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationTargeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Arkin, M. R., Tang, Y., & Wells, J. A. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.09.001 · Cited by 1,065
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Cited by
Delineating the RAS Conformational Landscape
Parker, M. I., Meyer, J. E., Golemis, E. A., & Dunbrack (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0804 · Cited by 30
De novo design of Ras isoform selective binders
Zhang, J. Z., Li, X., Batingana, A. R., Liu, C., Jiang, H., Shannon, K., Huang, B. J., Wu, K., & Baker, D. (2026) · Cell Chemical Biology · doi:10.1016/j.chembiol.2026.02.008 · Cited by 12
Structural characterization and inhibition of the interaction between ch-TOG and TACC3
Shelford, J., Burgess, S. G., Rostkova, E., Richards, M. W., Larocque, G., Sampson, J., Tiede, C., Fielding, A. J., Daviter, T., Tomlinson, D. C., et al. (2025) · Journal of Cell Biology · doi:10.1083/jcb.202407002 · Cited by 2
Self-citationData from Delineating the RAS Conformational Landscape
Parker, M. I., Meyer, J. E., Golemis, E. A., & Dunbrack (2023) · doi:10.1158/0008-5472.c.6513960.v1 · Cited by 1
Data from Delineating the RAS Conformational Landscape
Parker, M. I., Meyer, J. E., Golemis, E. A., & Dunbrack (2023) · doi:10.1158/0008-5472.c.6513960
Metadata
- Authors
- Haza, K. Z., Martin, H. L., Rao, A., Turner, A. L., Saunders, S. E., Petersen, B., Tiede, C., Tipping, K., Tang, A. A., Ajayi, M., Taylor, T., Harvey, M., Fishwick, K. M., Adams, T. L., Gaule, T. G., Trinh, C. H., Johnson, M., Breeze, A. L., Edwards, T. A., McPherson, M. J., & Tomlinson, D. C.
- Venue
- Nature Communications
- Published
- 2021-06-30
- Volume
- 12
- Issue
- 1
- Pages
- 4045-4045
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3176664740
- Cited by
- 41
- References
- 16
- FWCI
- 2.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site. https://app.cochat.ai/papers/10.1038/s41467-021-24316-0
- The paper
- Haza, K. Z., Martin, H. L., Rao, A., Turner, A. L., Saunders, S. E., Petersen, B., Tiede, C., Tipping, K., Tang, A. A., Ajayi, M., Taylor, T., Harvey, M., Fishwick, K. M., Adams, T. L., Gaule, T. G., Trinh, C. H., Johnson, M., Breeze, A. L., Edwards, T. A., . . . Tomlinson, D. C. (2021). RAS-inhibiting biologics identify and probe druggable pockets including an SII-α3 allosteric site. Nature Communications. https://doi.org/10.1038/s41467-021-24316-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.